Requip Xl

Parkinson Disease, Parkinson's Disease, Primary + 2 more
Treatment
7 FDA approvals
20 Active Studies for Requip Xl

What is Requip Xl

RopiniroleThe Generic name of this drug
Treatment SummaryRopinirole, also known as ReQuip, is a medication used to treat Parkinson's disease and restless legs syndrome. It was approved by the FDA in 1997 for Parkinson's disease and in 2005 for restless legs syndrome. In 2008, extended-release capsules were approved, allowing patients to take the medication less often while still having the same effectiveness and side effects as the original version. Ropinirole is manufactured by GlaxoSmithKline Pharmaceuticals.
Requipis the brand name
image of different drug pills on a surface
Requip Xl Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Requip
Ropinirole
1997
379

Approved as Treatment by the FDA

Ropinirole, otherwise called Requip, is approved by the FDA for 7 uses such as Severe restless legs syndrome (RLS) and Parkinson's Disease (PD) .
Severe restless legs syndrome (RLS)
Parkinson's Disease (PD)
Helps manage Parkinson's Disease (PD)
Moderate restless legs syndrome (RLS)
Primary
Restless Legs Syndrome
Restless Legs Syndrome
Parkinson's Disease
Helps manage Parkinson's Disease (PD)

Effectiveness

How Requip Xl Affects Patients**Effects on Parkinson's and Restless Leg Syndrome** This drug helps improve symptoms of Parkinson's or restless leg syndrome by stimulating the dopamine receptors in the body, which control movement. **Effects on Blood Pressure**Ropinirole can cause blood pressure changes in some people, leading to dizziness or fainting. This is believed to be due to a decrease in the body's ability to regulate blood pressure when standing. Nausea is also a common symptom with these blood pressure changes. **Effects on Prolactin**Taking as little as 0.2 mg of
How Requip Xl works in the bodyRopinirole is a drug that helps treat Parkinson's and Restless Legs Syndrome by stimulating certain dopamine receptors in the brain. It has the highest affinity for D3 receptors, which are found in the limbic areas of the brain, and it also stimulates D2 receptors in the caudate-putamen system. It has no effect on other receptors such as alpha2 adrenoreceptors, 5HT-1 receptors, or GABA receptors. We don't know exactly how it works to treat these conditions, but we think it is related to its ability to stimulate dopamine receptors.

When to interrupt dosage

The endorsed dosage of Requip Xl is subject to the diagnosed affliction, comprising of Restless Legs Syndrome, Restless Legs Syndrome and Parkinson's Disease. The quantity of dosage is contingent upon the delivery method specified in the table below.
Condition
Dosage
Administration
Restless Legs Syndrome
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Restless Legs Syndrome
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Parkinson Disease
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Parkinson's Disease
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral
Primary
, 12.0 mg, 6.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 0.25 mg, 0.5 mg, 1.0 mg, 3.0 mg, 5.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Requip Xl Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Ropinirole may interact with Pulse Frequency
There are 20 known major drug interactions with Requip Xl.
Common Requip Xl Drug Interactions
Drug Name
Risk Level
Description
Acebutolol
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Acebutolol.
Aliskiren
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Aliskiren.
Ambrisentan
Minor
Ropinirole may increase the hypotensive activities of Ambrisentan.
Amifostine
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Amifostine.
Amiloride
Minor
The risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride.
Requip Xl Toxicity & Overdose RiskOverdosing on ropinirole can cause agitation, chest pain, confusion, drowsiness, uncontrollable muscle movements, light-headedness when standing, nausea, and vomiting. Animal studies found an increase in tumors in male rats and uterine polyps in female mice at high doses. The drug was not found to be mutagenic or clastogenic. Ropinirole can disrupt implantation in pregnant rats, but no studies have been done in pregnant women. Pregnancy Category C means that it has the potential to cause harm to an unborn baby.

Requip Xl Novel Uses: Which Conditions Have a Clinical Trial Featuring Requip Xl?

51 active clinical trials are currently being conducted to assess the utility of Requip Xl in treating Restless Legs Syndrome, Parkinson Disease and related Restless Legs Syndrome symptoms.
Condition
Clinical Trials
Trial Phases
Parkinson Disease
8 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable
Restless Legs Syndrome
6 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2
Primary
0 Actively Recruiting
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Restless Legs Syndrome
0 Actively Recruiting

Requip Xl Reviews: What are patients saying about Requip Xl?

5Patient Review
1/21/2012
Requip Xl for Parkinson's Disease
Requip XL has helped me a lot during the day, but by early evening the effects seem to wear off and my RLS becomes quite painful. Soaking in a hot tub is usually the only thing that provides relief.
5Patient Review
3/12/2015
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
Ropinirole Er has been a huge help to me, however I have experienced some unexpected nocturnal urination. Has anyone else experienced this? Could there be a connection?
5Patient Review
8/2/2013
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
Though this medication has helped with my restless leg syndrome, it's also killed my sex drive. Unfortunately, that's led to some difficulties in my marriage.
5Patient Review
10/22/2013
Requip Xl for Parkinson's Disease
This treatment has greatly improved my quality of life.
5Patient Review
6/10/2018
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
I have severe restless legs syndrome.
4.7Patient Review
5/25/2012
Requip Xl for Parkinson's Disease
I experienced numbness in my left stomach and blurred vision after taking this medication.
4.3Patient Review
9/28/2011
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
It can sometimes take a little while for this to work, but it's worth being consistent with the dosage.
3.7Patient Review
9/10/2012
Requip Xl for Parkinson's Disease
Unfortunately, this drug had some pretty severe side effects for me. I was constantly awake and felt like I had to be doing something all the time. As a result, my quality of life suffered quite a bit. It took my doctor over a year to figure out what was wrong. So, in short, I would not recommend this drug to anyone.
3.3Patient Review
1/14/2012
Requip Xl for Parkinson's Disease
I've been taking RequipXL for about 12 years now and it's really helped me maintain an active lifestyle. I don't think I could continue playing golf 18 holes a day without it. The side effects have been manageable, although I would like to increase my dosage even more.
3.3Patient Review
7/24/2013
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
I take requipxl alongside other medication to help me get by.
1.3Patient Review
8/18/2012
Requip Xl for Parkinson's Disease
Withdrawal from this drug has been both gradual and horrifying. I experienced a range of symptoms including nausea, diarrhea, headaches, confusion, and abdominal pain. Please be very careful if you decide to stop taking this medication.
1Patient Review
1/21/2012
Requip Xl for Extreme Discomfort in Calves when Sitting or Lying Down
Requip XL time release was a complete game-changer for me. I had been struggling with nausea for years, and this medicine completely alleviated that issue. Additionally, my balance and tremor improved, and I was even able to pick up knitting again!
1Patient Review
8/1/2012
Requip Xl for Parkinson's Disease
I had a lot of negative reactions to this medication, including confusion, dizziness, headaches, and muscle spasms. I stopped taking it for a while, but now I only take half the dosage every other night.

Patient Q&A Section about requip xl

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does Requip XL last?

"The purpose of REQUIP XL is to provide a steady release of medication over the course of a day."

Answered by AI

What are the side effects from Requip?

"These are some of the side effects that may occur. If they persist or get worse, be sure to tell your doctor."

Answered by AI

What is Requip XL used for?

"Requip XL helps to restore the balance of dopamine in the brain in order to treat the symptoms of Parkinson's disease, such as stiffness, tremors, muscle spasms, and poor muscle control."

Answered by AI

How long does the extended-release ropinirole last?

"Ropinirole extended-release tablets are designed to release medication over a 24-hour period. If rapid gastrointestinal transit occurs, there is a risk of incomplete release of medication and medication residue being passed in the stool."

Answered by AI

Clinical Trials for Requip Xl

Have you considered Requip Xl clinical trials? We made a collection of clinical trials featuring Requip Xl, we think they might fit your search criteria.Go to Trials
Image of London Health Sciences Center.London ,Ontario in London, Canada.

Wearable Technology for Parkinson's Disease

18+
All Sexes
London, Canada
This study aims to evaluate whether wearable technology can improve the management of motor symptoms in people with Parkinson's disease (PD) who experience motor fluctuations throughout the day. The project will use a smartwatch and mobile app (KinesiaU) to continuously track movement, allowing for more responsive and personalized treatment compared to traditional monitoring methods. In this pilot randomized controlled trial, 32 participants will be assigned to either: A control group receiving standard care, or A wearable device group receiving standard care plus using the smartwatch. Outcomes will be assessed over a 4-week period, focusing on changes in motor function, quality of life, and self-management. The study will also examine feasibility, adherence, and data quality. If successful, this trial will provide critical evidence for integrating wearable devices into routine clinical care for PD, paving the way for larger efficacy trials and more patient-centered care strategies.
Waitlist Available
Has No Placebo
London Health Sciences Center.London ,Ontario (+1 Sites)
Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD
The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment
Phase 1 & 2
Waitlist Available
Kennedy Krieger InstituteAlison E Pritchard, PhD
Image of University of Florida, Norman Fixel Institute for Neurological Diseases in Gainesville, United States.

Deep Brain Stimulation for Parkinson's Disease

45 - 85
All Sexes
Gainesville, FL
Nearly one-million people in North America are now living with Parkinson's disease (PD), and that number is projected to rise to nearly 1.2 million by 2030. With advancements in neuromodulatory technologies, increasingly more of these individuals elect to undergo deep brain stimulation (DBS) surgery in order to control symptoms of the disease, including refractory tremor, medication-induced dyskinesias, and PD-associated dystonia. The two most common DBS neural targets for controlling these symptoms are the globus pallidus internal segment (GPi) and the subthalamic nucleus (STN). Recent meta-analyses have shown relative equivalence between these two sites at controlling core PD symptoms. To date, there is not conclusive evidence regarding the potential impact of DBS to GPi or STN on laryngeal-mediated functions of voice, swallowing, and cough, and consequently no guidance on whether these outcomes should be considered when selecting DBS target. Therefore, the goal of this project is to determine the impact of DBS neural target (STN versus GPi), lead location within the target, laterality, and stimulation settings on voice, swallow and cough function in people with PD. The larynx is an important player in each of these functions, and our central hypothesis is that spread of stimulation to corticobulbar fibers in the genu of the internal capsule have deleterious effects on laryngeal motor control, resulting in voice, swallow, and cough dysfunction. We have identified three specific aims for this application: 1.) To compare laryngeal function during volitional voice tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 2.) To compare laryngeal function during volitional and induced cough tasks pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. 3.) To compare airway safety associated with laryngeal onset, degree, and duration of maximum closure during swallowing, pre-post DBS, and when DBS placement is bilateral versus unilateral for STN and GPi targets. These hypotheses were developed based on compelling published and unpublished preliminary data. We will accomplish these aims by enrolling people with PD who are being considered for DBS surgery. We will measure physiologic, functional, and quality of life parameters of voice, swallow and cough pre- and post-surgically. The realization of the proposed aims is significant because it will address a substantial gap in our understanding of DBS outcomes related to communication and airway protection, which are important in terms of morbidity, mortality, and quality of life for patients with PD. The translational potential to provide additional guidance to DBS surgical teams regarding whether voice, swallow or cough functions should be considered with selecting DBS target and/or laterality is high. Ultimately, the project fits squarely within the overarching goal of the research team to deliver the best possible care to people with PD.
Recruiting
Has No Placebo
University of Florida, Norman Fixel Institute for Neurological DiseasesKaren Hegland, Ph.D.
Have you considered Requip Xl clinical trials? We made a collection of clinical trials featuring Requip Xl, we think they might fit your search criteria.Go to Trials
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Cannabis for Restless Legs Syndrome

18+
All Sexes
Toronto, Canada
Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.
Recruiting
Drug
Sunnybrook Health Sciences Centre (+1 Sites)
Image of Integrated Health and Movement Science Laboratory, Saint Louis University in St. Louis, United States.

Community Walking Program for Parkinson's Disease

30 - 85
All Sexes
St. Louis, MO
This study will investigate the feasibility of a 6-month community walking program for people with Parkinson's disease (PD) and their care partners in greater Saint Louis, Missouri region. The walking program will consist of weekly, organized walking groups at the Missouri Botanical Gardens. Participants in the program will use Nordic walking poles during the walks. The walking group(s) will meet once per week and will be supervised by walking group leaders from Saint Louis University. Participants will be given a smart watch to wear that will help step counts will be tracked in real-time. The program is designed to get people with Parkinson's disease out of their homes, cultivate a culture of connection with others with Parkinson's disease, and to be collectively accountable for a common goal toward increasing their physical and social engagement in their communities.
Recruiting
Has No Placebo
Integrated Health and Movement Science Laboratory, Saint Louis University (+1 Sites)
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Have you considered Requip Xl clinical trials? We made a collection of clinical trials featuring Requip Xl, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security